Company Overview of Nokad S.A.
Nokad S.A., a biotechnology company, develops a functional-inactivation technology for secreted proteins in vivo in mammals through induction of a specific immune response against the endogenous targets. Its technology platform allows switch from one strain to another or from one species to another to help scientist accelerate the target validation programs while minimizing the risk of missing key information in view of clinical applications. The company was founded in 2004 and is headquartered in Evry, France with an additional office in Cambridge, Massachusetts.
4 rue Pierre Fontaine
Building CCI Essonne
Founded in 2004
33 1 60 87 89 90
33 1 60 87 89 99
Key Executives for Nokad S.A.
Similar Private Companies By Industry
|Acticor Biotech SAS||Europe|
|Aelis Farma S.A.S.||Europe|
|Aenitis Technologies SAS||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|NYC2012, Inc.||United States|
|Tax Management Inc||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Nokad S.A., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.